Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03998566 · ClinicalTrials.gov registry record · NA
Radiopaque Hydrogel Spacer in Patients Undergoing Radiotherapy for Pancreatic Cancer
A NA study of Pancreatic Cancer, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 6
- Enrollment target
- 3
- Study locations
NCT03998566: Completed NA study of Pancreatic Cancer, sponsored by Boston Scientific Corporation.
NCT03998566 is a NA study of Pancreatic Cancer that has completed, run by Boston Scientific Corporation. The registered enrollment target is 6 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03998566, a NA study of Pancreatic Cancer, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
- 3
- Study locations
Study Summary
An early feasibility study to evaluate feasibility, radiotherapy benefits and safety when using TraceIT tissue spacer to create space between pancreas and duodenum in patients with localized Pancreatic Cancer.
Primary Outcome
Number of subjects with TraceIT procedure-related event which resulted in a delay in initiation for RT (radio-therapy).
Conditions Studied
Interventions
- DEVICE TraceIT Tissue Spacer implantation
Study Locations (3)
Maryland
- Johns Hopkins Medicine - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-04-24 |
| Est. Completion | 2021-05-01 |
| Phase | NA |
What the finished NCT03998566 record still lists
NCT03998566 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which TraceIT Tissue Spacer implantation is the first listed.
NCT03998566 reports a single indexed study location in Maryland, Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT03998566 about?
NCT03998566 is a clinical study titled "Radiopaque Hydrogel Spacer in Patients Undergoing Radiotherapy for Pancreatic Cancer". An early feasibility study to evaluate feasibility, radiotherapy benefits and safety when using TraceIT tissue spacer to create space between pancreas and duodenum in patients with localized Pancreatic Cancer.
What is the current status of trial NCT03998566?
This trial is currently completed. It is a NA study. The enrollment target is 6 participants. The study started on 2019-04-24. Estimated completion is 2021-05-01.
What conditions does trial NCT03998566 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT03998566?
The interventions under investigation include: TraceIT Tissue Spacer implantation (DEVICE).
Who is sponsoring clinical trial NCT03998566?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03998566 being conducted?
This trial has 3 study locations across Maryland, Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03998566's enrollment target sits among peer trials
6 273rd of 278 higher than 5 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope
RECRUITING · NA
-
Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer
RECRUITING · NA
-
Support Through Remote Observation and Nutrition Guidance Program (STRONG-PCS)
RECRUITING · NA
-
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI